Ovation Science Inc. (OVATF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ovation Science Inc. (OVATF) trades at $0.04 with AI Score 61/100 (Grade B+). Ovation Science Inc. develops and markets cannabis and hemp-infused topical and transdermal products utilizing its patented Invisicare drug delivery technology. Market cap: $1.35M, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for OVATF: OVATF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OVATF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
OVATF: 2/4 perspectives are bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Ovation Science Inc. (OVATF) Healthcare & Pipeline Overview
Ovation Science Inc. specializes in cannabis and hemp-infused topical and transdermal products, leveraging its patented Invisicare drug delivery technology. The company operates across Canada, the United States, and Mexico, offering health, wellness, and skincare solutions under brands like Ovation, BASKiN, Invibe MD, ARLO CBD, and DermSafe.
What Is the Investment Thesis for OVATF?
Ovation Science Inc. presents a research focus centered on its patented Invisicare drug delivery technology, a key differentiator in the expanding topical and transdermal cannabis and hemp product markets. This proprietary technology offers a potential competitive advantage by enhancing the efficacy and absorption of active ingredients in skincare and wellness solutions. The company's diversified brand portfolio, including Ovation, BASKiN, Invibe MD, ARLO CBD, and DermSafe, along with its geographic reach across Canada, the United States, and Mexico, positions it to capitalize on various segments of the evolving cannabis and health product industries. While the company's current financial metrics, including a profit margin of -934.2% and a gross margin of -245.9%, indicate significant operational challenges and unprofitability, the long-term value proposition hinges on the successful commercialization and market adoption of its Invisicare-powered products. Monitoring revenue growth, cost management, and market penetration in its key operating regions will be crucial for assessing the company's trajectory.
Based on FMP financials and quantitative analysis
OVATF Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or nano-cap entity with a very small public valuation.
- Profit Margin: -934.2%, reflecting substantial operational losses relative to its revenue base, highlighting significant unprofitability.
- Gross Margin: -245.9%, suggesting that the cost of goods sold significantly exceeds revenue, indicating challenges in product pricing or production efficiency.
- Beta: 0.44, indicating lower volatility compared to the broader market, suggesting less sensitivity to overall market movements.
- Dividend Yield: None, consistent with a company that is either in a growth phase, prioritizing reinvestment, or currently unprofitable.
Who Are OVATF's Competitors?
OVATF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALVO Alvotech | $3.51 | -2.77% | $1.19B | 69 |
| AERI Aerie Pharmaceuticals, Inc. | $15.25 | +0.00% | 68 | |
| KIN Kindred Biosciences, Inc. | $9.25 | +0.11% | 68 | |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109.16M | 66 |
| NPNKF Nippon Shinyaku Co., Ltd. | $32.75 | +4.30% | $2.21B | 61 |
| INNPF INNOCAN PHARMA Corp | $1.60 | -8.05% | $7.20M | 61 |
| ETST Earth Science Tech, Inc. | $0.17 | +25.56% | $48.85M | 61 |
| DCPH Deciphera Pharmaceuticals | $25.59 | +0.08% | $2.21B | 61 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OVATF's Key Strengths?
- Proprietary patented Invisicare drug delivery technology for enhanced topical/transdermal efficacy.
- Diverse product portfolio catering to health, wellness, and skincare segments (Invibe MD, ARLO CBD, DermSafe).
- Established presence and operations across Canada, the United States, and Mexico.
- Strategic sublicenses and partnerships with licensed dispensaries for market access.
What Are OVATF's Weaknesses?
- Significant unprofitability with a profit margin of -934.2% and gross margin of -245.9%.
- Small market capitalization ($0.00B) indicating limited financial resources and market presence.
- Trades on the OTC market, which can imply lower liquidity and transparency.
- Reliance on evolving and complex cannabis and hemp regulatory frameworks across different geographies.
What Could Drive OVATF Stock Higher?
- Potential for new product launches utilizing the Invisicare technology in the cannabis or hemp-derived health and wellness markets, which could drive revenue growth.
- Expansion of distribution channels and partnerships within the United States, particularly through additional licensed dispensaries, to increase market reach for its cannabis-based products.
- Regulatory advancements in key operating regions (US, Canada, Mexico) that could further liberalize cannabis and hemp markets, potentially expanding addressable market opportunities.
- Successful commercialization of Invisicare technology in non-cannabis applications, potentially through licensing agreements with other healthcare or cosmetic companies, diversifying revenue streams.
What Are the Key Risks for OVATF?
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant unprofitability, as evidenced by a -934.2% profit margin and -245.9% gross margin, indicating challenges in achieving sustainable financial performance.
- High operational costs and potential for insufficient capital to fund ongoing research, development, and market expansion initiatives.
- Intense competition within the rapidly evolving cannabis and hemp product markets, which could pressure pricing and market share.
- Regulatory uncertainty and changes in the legal status of cannabis and hemp products across different jurisdictions, posing risks to market access and product legality.
- Limited investor transparency due to the 'Unknown' disclosure status on the OTC Other tier, hindering informed decision-making and potentially impacting investor confidence.
What Are the Growth Opportunities for OVATF?
- Expansion of Invisicare Technology Applications: The patented Invisicare drug delivery technology represents a significant growth opportunity beyond current applications. By exploring new therapeutic areas or product categories within the healthcare and wellness sectors, Ovation Science could license its technology or develop new product lines. For instance, the transdermal delivery market for various compounds is projected to grow, with potential applications in pain management, anti-inflammatory treatments, or even cosmetic dermatology, offering a substantial addressable market. Successful R&D and commercialization in these new areas could unlock significant revenue streams over the next 3-5 years.
- Geographic Market Penetration: Ovation Science currently operates in Canada, the United States, and Mexico. Deepening market penetration within these existing geographies, particularly in the United States where cannabis regulations are evolving, presents a substantial growth avenue. The U.S. cannabis market alone is estimated to reach tens of billions of dollars annually. By strategically expanding its distribution networks, securing additional sublicenses, and forging partnerships with more licensed dispensaries, the company can capture a larger share of these markets over the short to medium term (1-3 years), leveraging its established brand presence.
- Diversification of Product Lines: The company's existing portfolio includes Invibe MD (CBD health/wellness), ARLO CBD (skincare), and DermSafe (hand sanitizers). Further diversification within these categories or into adjacent ones, such as ingestible CBD products or specialized medical cannabis formulations, could broaden its customer base. The global CBD market is projected to reach over $50 billion by 2028, indicating significant room for new product development. Introducing innovative products that address specific consumer needs or health conditions could drive sustained revenue growth over a 2-4 year horizon.
- Leveraging Sublicenses and Partnerships: Ovation Science holds sublicenses for cannabis-based products and has a relationship with Lighthouse for licensed dispensaries in the United States. Expanding these strategic partnerships and securing additional sublicenses in new states or regions can significantly accelerate market access and distribution. Collaborations with larger pharmaceutical or consumer goods companies could provide capital, manufacturing capabilities, and broader distribution channels. Such strategic alliances could unlock market opportunities and scale operations more rapidly, with potential impacts seen within 1-2 years.
- Growth in Topical/Transdermal Cannabis Market: The market for topical and transdermal cannabis and hemp products is experiencing robust growth as consumers seek localized relief and non-intoxicating options. Ovation Science's focus on this segment, underpinned by its Invisicare technology, positions it well to capture this demand. The global topical pain relief market, which includes many potential applications for cannabis topicals, is a multi-billion dollar industry. Continued consumer education and increasing acceptance of cannabis-derived products for therapeutic use will fuel this growth, providing a favorable environment for Ovation Science's core offerings over the next 3-5 years.
What Opportunities Does OVATF Have?
- Expansion of Invisicare technology into new therapeutic areas or product categories within healthcare.
- Deepening market penetration and distribution in existing geographic markets, particularly the growing U.S. cannabis sector.
- Further diversification of CBD and hemp-based product lines to capture broader consumer demand.
- Formation of additional strategic partnerships or licensing agreements to scale operations and market reach.
What Threats Does OVATF Face?
- Intense competition from both established pharmaceutical companies and specialized cannabis product manufacturers.
- Adverse changes in cannabis and hemp regulations, potentially impacting market access or product legality.
- Challenges in achieving profitability and managing high operational costs.
- Public perception shifts or scientific findings that could impact consumer trust in cannabis/hemp products.
What Are OVATF's Competitive Advantages?
- Patented Invisicare drug delivery technology, offering a proprietary method for topical and transdermal absorption.
- Diverse portfolio of established brands including Ovation, BASKiN, Invibe MD, ARLO CBD, and DermSafe.
- Sublicenses for cannabis-based products, providing legal frameworks for operation in regulated markets.
- Strategic relationships with licensed dispensaries in the United States for product distribution.
What Does OVATF Do?
Ovation Science Inc., incorporated in 2017 and headquartered in Vancouver, Canada, is engaged in the production and commercialization of cannabis and hemp-based products across Canada, the United States, and Mexico. The cornerstone of its product development is Invisicare, a proprietary, patented drug delivery technology designed for use in topical and transdermal skincare products. This innovative technology is applied to formulations containing hemp seed oil and cannabis, forming the basis for products marketed under the Ovation and BASKiN brands. Beyond these core offerings, Ovation Science has diversified its portfolio to address various consumer needs within the health and wellness sector. The company offers cannabidiol (CBD) infused health and wellness solutions under the Invibe MD brand, catering to a growing demand for natural wellness alternatives. Additionally, it provides specialized skincare solutions under the ARLO CBD name, focusing on the therapeutic potential of CBD in dermatological applications. In response to broader public health needs, Ovation Science also manufactures hand sanitizers under the DermSafe brand. The company's operational model includes holding sublicenses for cannabis-based products, which facilitates its market access and product distribution. Furthermore, it maintains a relationship with Lighthouse for licensed dispensaries in the United States, indicating a strategic approach to reaching consumers through established retail channels. Ovation Science Inc. positions itself within the specialty and generic drug manufacturing industry, emphasizing its unique delivery technology and diverse product range.
What Products and Services Does OVATF Offer?
- Develops and produces cannabis and hemp-infused topical and transdermal products.
- Utilizes its patented Invisicare drug delivery technology for enhanced product efficacy.
- Markets products under its own brands: Ovation and BASKiN for cannabis/hemp skincare.
- Offers cannabidiol (CBD) infused health and wellness solutions under the Invibe MD brand.
- Provides specialized CBD skincare solutions through the ARLO CBD brand.
- Manufactures hand sanitizers under the DermSafe brand.
- Holds sublicenses for cannabis-based products to facilitate market access.
- Engages with Lighthouse for distribution to licensed dispensaries in the United States.
How Does OVATF Make Money?
- Generates revenue from the sale of branded topical and transdermal cannabis and hemp products.
- Monetizes its patented Invisicare technology through product development and potentially licensing agreements.
- Distributes products through licensed dispensaries and potentially direct-to-consumer channels.
- Operates across Canada, the United States, and Mexico, adapting to regional regulatory frameworks.
What Industry Does OVATF Operate In?
Ovation Science Inc. operates within the dynamic and rapidly evolving Drug Manufacturers - Specialty & Generic industry, specifically focusing on cannabis and hemp-derived topical and transdermal products. This segment is characterized by increasing consumer interest in alternative health and wellness solutions, alongside a complex and varying regulatory landscape across different jurisdictions. The global cannabis market, including both medical and recreational segments, continues to expand, with topical applications gaining traction for localized relief without systemic effects. Ovation Science differentiates itself through its patented Invisicare drug delivery technology, aiming to enhance product efficacy in a crowded market. Competition is intense, encompassing both established pharmaceutical companies exploring cannabis derivatives and numerous specialized cannabis product manufacturers. The company's positioning relies on its proprietary technology to carve out a niche within this competitive landscape, targeting consumers seeking advanced delivery methods for cannabis and hemp compounds.
Who Are OVATF's Key Customers?
- Consumers seeking health and wellness solutions infused with cannabidiol (CBD).
- Individuals looking for specialized skincare products utilizing CBD.
- Consumers interested in topical and transdermal applications of cannabis and hemp for localized effects.
- Licensed cannabis dispensaries in the United States.
- Retailers and distributors of health, wellness, and personal care products.
Company Profile
Ovation Science Inc. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Vancouver, CA. The company is led by CEO Terry H. Howlett. OVATF has traded publicly since 2019.
How Ovation Science Inc. Is Valued
Ovation Science Inc. carries a market capitalization of $1.35M, placing it in the micro-cap category. Relative to its peer group, OVATF's quantitative score of 61/100 is roughly in line with the peer average of 66/100.
ROE 43%Key Financial Metrics
Return on equity for Ovation Science Inc. stands at 42.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -10.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -80.0%, the inverse of the P/E and a quick read on earnings relative to price.
F-Score 3/9Financial Health
Ovation Science Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
OVATF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Proprietary patented Invisicare drug delivery technology for enhanced topical/transdermal efficacy.
- Diverse product portfolio catering to health, wellness, and skincare segments (Invibe MD, ARLO CBD, DermSafe).
- Established presence and operations across Canada, the United States, and Mexico.
- Strategic sublicenses and partnerships with licensed dispensaries for market access.
Bear Case
- Significant unprofitability with a profit margin of -934.2% and gross margin of -245.9%.
- Small market capitalization ($0.00B) indicating limited financial resources and market presence.
- Trades on the OTC market, which can imply lower liquidity and transparency.
- Reliance on evolving and complex cannabis and hemp regulatory frameworks across different geographies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
OVATF Latest News
No recent news available for OVATF.
OVATF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OVATF.
Price Targets
Wall Street price target analysis for OVATF.
OVATF MoonshotScore
What does this score mean?
The MoonshotScore rates OVATF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Terry H. Howlett
CEO
Terry H. Howlett serves as the Chief Executive Officer of Ovation Science Inc. Specific details regarding his extensive career history, educational background, and previous executive roles prior to joining Ovation Science are not publicly available in the provided data. His professional experience is understood to be within the relevant industry, guiding the company's strategic direction and operational execution.
Track Record: Under Terry H. Howlett's leadership, Ovation Science Inc. has focused on developing and commercializing its patented Invisicare drug delivery technology for cannabis and hemp products. Key milestones include the establishment of product lines under brands such as Ovation, BASKiN, Invibe MD, ARLO CBD, and DermSafe, and the expansion of operations into Canada, the United States, and Mexico. His tenure has seen the company navigate the complexities of the emerging cannabis market.
OVATF OTC Market Information
Ovation Science Inc. trades on the OTC Other tier, which is the lowest tier of the OTC Markets Group. This tier is typically for companies that do not meet the disclosure or financial standards of higher tiers like OTCQX or OTCQB, or major exchanges like NYSE or NASDAQ. Companies in the OTC Other tier may not provide current information to the public, or they may be in financial distress. This classification implies a significantly higher risk profile compared to exchange-listed securities, primarily due to limited transparency and oversight.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited Transparency: The 'Unknown' disclosure status means critical financial and operational information is not consistently available, hindering informed investment decisions.
- Low Liquidity: Trading on the OTC Other tier with a $1.35M market cap suggests very low trading volume, making it difficult to buy or sell shares without significantly impacting the price.
- Price Volatility: Low liquidity and limited information can lead to extreme price fluctuations, making the stock highly volatile and unpredictable.
- Lack of Regulatory Oversight: Companies on the OTC Other tier are subject to minimal regulatory scrutiny compared to major exchanges, increasing the risk of fraud or mismanagement.
- Difficulty in Valuation: Without reliable and current financial data, accurately valuing the company's assets, liabilities, and future prospects becomes highly speculative.
- Attempt to locate any available financial statements or company updates through alternative sources, even if not officially disclosed on OTC Markets.
- Research any news or press releases issued by the company directly, if available, to understand recent developments.
- Investigate the background and track record of the management team beyond what is publicly stated.
- Assess the current market and regulatory environment for cannabis and hemp products in Canada, the US, and Mexico.
- Analyze the competitive landscape and Ovation Science's unique positioning, if discernible.
- Evaluate the company's intellectual property (Invisicare technology) and its actual commercialization progress.
- Consider the potential for delisting or further restrictions if disclosure status remains unknown or worsens.
- Possession of a patented drug delivery technology (Invisicare) suggests a foundation in R&D and intellectual property.
- Operation across multiple countries (Canada, US, Mexico) indicates a broader scope of business activity.
- Development and marketing of multiple distinct product brands (Ovation, BASKiN, Invibe MD, ARLO CBD, DermSafe).
- Incorporation in 2017 and a headquarters in Vancouver, Canada, providing a verifiable corporate structure.
Common Questions About OVATF (Healthcare)
What does Ovation Science Inc. do?
Ovation Science Inc. is a Canadian company focused on the production and commercialization of cannabis and hemp-based products across Canada, the United States, and Mexico. Its core offering revolves around Invisicare, a patented drug delivery technology designed for topical and transdermal applications of hemp seed oil and cannabis. The company markets a range of products under various brands, including Ovation and BASKiN for cannabis/hemp skincare, Invibe MD for CBD-infused health and wellness solutions, ARLO CBD for specialized skincare, and DermSafe for hand sanitizers. Ovation Science also holds sublicenses for cannabis-based products and partners with licensed dispensaries to distribute its offerings, positioning itself in the specialty drug manufacturing segment of the healthcare industry.
What are the key challenges for Ovation Science Inc. in the cannabis and hemp product market?
Ovation Science Inc. faces several significant challenges within the cannabis and hemp product market. A primary concern is the complex and often inconsistent regulatory landscape across its operating regions in Canada, the United States, and Mexico, which can impact product legality, market access, and operational compliance. The market is also highly competitive, with numerous players ranging from large pharmaceutical companies to specialized cannabis firms, creating pressure on pricing and market share. Furthermore, the company's current financial performance, marked by substantial negative profit and gross margins, indicates ongoing operational inefficiencies and challenges in achieving profitability, which could hinder its ability to fund future growth and innovation in this capital-intensive sector.
How does Ovation Science Inc.'s Invisicare technology differentiate its products?
Ovation Science Inc.'s Invisicare technology serves as a core differentiator for its product portfolio in the competitive cannabis and hemp-based topical market. Invisicare is a patented drug delivery technology specifically designed to enhance the absorption and efficacy of active ingredients in topical and transdermal skincare products containing hemp seed oil and cannabis. This proprietary technology aims to improve the delivery of cannabinoids and other compounds through the skin, potentially leading to more effective or faster-acting results compared to conventional topical formulations. By leveraging Invisicare, Ovation Science seeks to provide superior product performance, offering a unique value proposition to consumers seeking advanced and efficient delivery methods for their health, wellness, and skincare needs.
What are the key factors to evaluate for OVATF?
Ovation Science Inc. (OVATF) holds an AI score of 61/100 (moderate). Not financial advice.
How frequently does OVATF data refresh on this page?
OVATF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven OVATF's recent stock price performance?
Ovation Science Inc. (OVATF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary patented Invisicare drug delivery technology for enhanced topical/transdermal efficacy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OVATF overvalued or undervalued right now?
Valuing Ovation Science Inc. (OVATF) requires multiple metrics. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying OVATF?
Before investing in Ovation Science Inc. (OVATF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial metrics like Market Cap, Profit Margin, and Gross Margin are directly from provided data.
- CEO background and track record are limited due to lack of detailed source information, resulting in 'Unknown' for specific details.
- Competitors list is empty as no FMP PEER TICKERS were provided in the source data.
- OTC disclosure status is 'Unknown' as per source data, which significantly impacts the depth of analysis possible.